STAT3 and Alzheimer disease: Considering that the transcriptional activity of STAT3 occurs after its acetylation, we administered a STAT3 dominant negative (STAT3DN) variant with lost deacetylation ability at K679, K685, K707, and K709 (K679QK685QK707QK709Q) to PQQ‐treated AD mice using an adenovirus delivery system (Figure 7f).